Skip Navigation



Hum. Reprod. Advance Access published online on June 20, 2008
Human Reproduction, doi:10.1093/humrep/den230
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
23/9/2127    most recent
den230v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Romualdi, D.
Right arrow Articles by Guido, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romualdi, D.
Right arrow Articles by Guido, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective

D. Romualdi1,3, B. Costantini1, L. Selvaggi1, M. Giuliani1, F. Cristello1, F. Macrì1, A. Bompiani1, A. Lanzone1,2 and M. Guido1

1 Department of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168 Rome, Italy 2 ‘Oasi’ Institute for Research, 94018 Troina (EN), Italy

3 Correspondence address. Tel/Fax: +39-06-3057794; E-mail: danielaromualdi{at}libero.it

BACKGROUND: Metformin was reported to improve the alterations of endothelial reactivity in normal-weight subjects with polycystic ovary syndrome (PCOS). The aim of the present study was to investigate the mechanisms of action of this drug on the vascular function of this population.

METHODS: Thirteen normal-weight, normoinsulinemic and normolipemic PCOS women were studied before and after 6 months of metformin treatment (1000 mg/day). The endothelial function was assessed by evaluating the flow-mediated dilatation (FMD) of the brachial artery. We correlated this parameter with the endocrine-metabolic features of the patients.

RESULTS: Metformin significantly reduced testosterone (1.56 ± 0.52 after 6 months versus 2.98 ± 1.00 at baseline) and 17-hydroxyprogesterone (0.03 ± 0.01 versus 0.06 ± 0.02 nmol/ml) levels, without affecting gluco-insulinemic parameters. Concomitantly, the basal vessel diameter and the FMD significantly increased (4.12 ± 0.68 versus 3.2 ± 0.41 and 5.2 ± 0.6 versus 3.76 ± 0.5 mm, respectively), thus documenting an improved endothelial function.

CONCLUSIONS: Our data confirm the positive effects of metformin on the altered vascular reactivity, a precocious marker of cardiovascular risk, in normoinsulinemic PCOS subjects. This improvement seems to be mediated through hormonal changes, thus highlighting the detrimental role of hyperandrogenemia on the endothelial function, even beyond the metabolic factors. However, a direct effect of metformin on the endothelium should not be excluded.

Key words: polycystic ovary syndrome/cardiovascular disease/endothelial function/androgens/metformin

Submitted on January 11, 2008; resubmitted on May 12, 2008; accepted on May 19, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr.
Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
Endocr. Rev., February 1, 2009; 30(1): 1 - 50.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.